Targeting PI3K/mTOR Signaling

Nov. 30-Dec. 3, 2018
Westin Boston Waterfront
Boston, Massachusetts

Conference Cochairs
Lewis C. Cantley
, Meyer Cancer Center, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York
David M. Sabatini
, MIT Whitehead Institute for Biomedical Research, Cambridge, Massachusetts
Jean J. Zhao
, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

The PI3K-mTOR signaling pathway is one of the most frequently dysregulated signaling cascades in cancer. This AACR Special Conference will highlight recent progress in understanding the molecular wiring of the PI3K-mTOR signaling network and its activation in cancer, the major downstream functions contributing to cancer pathology, and therapeutic strategies for targeting the network. This program will span from basic science to the most recent clinical advances, thus providing a forum for active discussion and collaboration among all sectors in the cancer workforce. The conference will cover topics including the biology of the PI3K/mTOR pathway, translational control in cancer, autophagy, immunology, structural biology, and the latest updates from clinical trials.

Professional Educational Grants